[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR950703331A - 하이드로겔 서방성 제제(Sustained-release hydrogel preparation) - Google Patents

하이드로겔 서방성 제제(Sustained-release hydrogel preparation) Download PDF

Info

Publication number
KR950703331A
KR950703331A KR1019950701051A KR19950701051A KR950703331A KR 950703331 A KR950703331 A KR 950703331A KR 1019950701051 A KR1019950701051 A KR 1019950701051A KR 19950701051 A KR19950701051 A KR 19950701051A KR 950703331 A KR950703331 A KR 950703331A
Authority
KR
South Korea
Prior art keywords
formulation
hydrogel
additive
release
amount
Prior art date
Application number
KR1019950701051A
Other languages
English (en)
Other versions
KR100355130B1 (ko
Inventor
가즈히로 사코
히로시 나카시마
도요히로 사와다
아키라 오카다
무네오 후쿠이
Original Assignee
오노다 마사요시
야마노우치 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26490061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR950703331(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 오노다 마사요시, 야마노우치 세이야쿠 가부시키가이샤 filed Critical 오노다 마사요시
Publication of KR950703331A publication Critical patent/KR950703331A/ko
Application granted granted Critical
Publication of KR100355130B1 publication Critical patent/KR100355130B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은, 하나 이상의 약물, 제제의 코어내로 물을 침투시키기 위한 첨가물 및 하이드로겔을 형성하는 거대분자 물질을 포함하는 하이드로겔 서방성 제제에 관한 것이다. 이는 위 및 소장과 같은 상부 소화관내에 머무르는 동안 실질적으로 완전한 겔화를 일으킬 수 있으며 결장을 포함한 하부 소화관 내에서도 약물을 방출시킬 수 있다.
당해 제제는 결장에서도 약물의 효과적인 방출 및 흡수가 가능하게 하여 안정한 서방성 효과를 성취할 수 있게 한다.

Description

하이드로겔 서방성 제제(Sustained-release hydrogel preparation)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 PEG6000-하유 하이드로겔-타입 서방성 제제를 사용한 겔화 테스트의 결과를 나타낸다.
제2도는 PEG6000 함량이 다양한 제제를 사용한 겔화 테스트의 결과를 나타낸다.
제3도는 2시간후의 여러가지 친수성 기재의 겔화지수를 나타낸다.
제4도는 POLYOX303의 양과 방출 패턴간의 관계(약물:아세트아미노펜)를 나타낸다.
제5도는 POLYOX303의 양과 방출 패턴간의 관계(약물:니카디핀 하이들로클로라이드)를 나타낸다.

Claims (8)

  1. (1) 하나 이상의 약물,(2) 제제의 코어내로 물을 침투시키기 위한 척가물 및 (3) 하이드로겔-형성 중합체를 포함하는, 위 및 소장을 포함하는 상부 소화관내에 머무르는 동안 실질적으로 완전한 겔화를 일으킬 수 있으며 결장을 포함한 하부 소화관내에서도 약물을 방출시킬 수 있는 하이드로겔 서방성 제제.
  2. 제1항에 있어서, 제제의 코어내로 물을 침투시키기 위한 첨가물이, 이 첨가물 1g을 용해시키는데 요구되는 물의 용량이 5ml 이하가 되는 용해도를 갖는 하나 이상의 첨가물인 하이드로겔 서방성 제제.
  3. 제2항에 있어서, 제제의 코어내로 물을 침투시키기 위한 첨가물이, 이 첨가물 1g을 용해시키는데 요구되는 물의 용량이 4ml 이하기 되는 용해도를 갖는 하나 이상의 첨가물인 하이드로겔 서방성 제제.
  4. 제1항에 있어서, 하이드로겔-형성 중합체가 2,000,000 이상의 평균 분자량을 갖는 중합체 또는 25℃이하 수중 1% 농도에서 측정할때 1000cps 이상의 점도를 갖는 중합체이거나, 또는 이들 중합체의 둘 이상의 혼합물인 하이드로겔 서방성 제제.
  5. 제1항 또는 제4항에 있어서, 하이드로겔-형성 중합체가 하나 이상의 폴리에틸렌 옥사이드를 포함하는 하이드로겔 서방성 제제.
  6. 제1항 내지 5항 중 어느 한 항에 있어서, (1) 전체 제제를 기준으로 하여 85중량% 이하의 양으로 존재하는 하나 이상의 약물, (2) 전체 제제를 기준으로 하여 5 내지 80중량%의 양으로 존재하는, 제제의 코어내로 물을 침투시키기 위한 첨가물 및 (3) 전체 제제를 기준으로 하여 10 내지 95중량%의 양으로 존재하는 하이드로겔-형성 중합체를 포함하는 하이드로겔 서방성 제제.
  7. 제1하에 내지 제6항중 어느 한 항에 있어서, (1)전체 제제를 기준으로 하여 80중량% 이하의 양으로 존재하는 하나 이상의 약물, (2) 전체 제제를 기준으로 5 내지 60중량%의 양으로 존재하는, 제제의 코어내로 물을 침투시키기 위한 첨가물 및 (3) 전체 제제를 기준으로 하여 15 내지 90중량%의 양으로 존재하는 하이드로겔-형성 중합체를 포함하는 하이드로겔 서방성 제제.
  8. 제1항 내지 제7항 중 어느 한 항에 있어서, 약물이 니카디핀 하이드로클로라이드인 하이드로겔 서방성 제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950701051A 1992-09-18 1993-09-10 하이드로겔서방성정제 KR100355130B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP92-274979 1992-09-18
JP27497992 1992-09-18
JP92-165263 1993-06-08
JP93-165263 1993-06-08
JP16526393 1993-06-08
PCT/JP1993/001297 WO1994006414A1 (en) 1992-09-18 1993-09-10 Sustained-release hydrogel preparation

Publications (2)

Publication Number Publication Date
KR950703331A true KR950703331A (ko) 1995-09-20
KR100355130B1 KR100355130B1 (ko) 2003-01-30

Family

ID=26490061

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950701051A KR100355130B1 (ko) 1992-09-18 1993-09-10 하이드로겔서방성정제

Country Status (23)

Country Link
US (3) US6436441B1 (ko)
EP (1) EP0661045B1 (ko)
JP (1) JP3140465B2 (ko)
KR (1) KR100355130B1 (ko)
CN (1) CN1048397C (ko)
AT (1) ATE219933T1 (ko)
AU (1) AU682827B2 (ko)
BG (1) BG61861B1 (ko)
CA (1) CA2144077C (ko)
CZ (1) CZ291495B6 (ko)
DE (1) DE69332081T2 (ko)
DK (1) DK0661045T3 (ko)
ES (1) ES2179829T3 (ko)
FI (1) FI115697B (ko)
HU (1) HU226456B1 (ko)
NO (1) NO312811B1 (ko)
NZ (1) NZ255579A (ko)
PL (1) PL175026B1 (ko)
PT (1) PT661045E (ko)
RO (1) RO112991B1 (ko)
RU (1) RU2121830C1 (ko)
SK (1) SK281042B6 (ko)
WO (1) WO1994006414A1 (ko)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO112991B1 (ro) * 1992-09-18 1998-03-30 Yamanouchi Pharma Co Ltd Preparat tip hidrogel, cu eliberare sustinuta
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
EP0761209A3 (en) * 1995-09-01 1998-02-04 J.B. Chemicals & Pharmaceuticals Ltd. Controlled release formulations of ranitidine
WO1997049384A1 (en) * 1996-06-26 1997-12-31 Board Of Regents, The University Of Texas System Hot-melt extrudable pharmaceutical formulation
ZA976189B (en) * 1996-07-12 1999-01-11 Novartis Consumer Health Sa Oral pharmaceutical combinations
GB9720797D0 (en) * 1997-09-30 1997-12-03 Rhodes John Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
US8679534B2 (en) * 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
DE19901040A1 (de) * 1999-01-14 2000-07-20 Knoll Ag Arzneiformen mit gesteuerter Freisetzung, enthaltend gut wasserlösliche Wirkstoffe
EG23951A (en) 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
NZ530701A (en) * 1999-06-04 2005-09-30 Alza Corp Implantable gel compositions comprising compressed particles including the active agent in a bioerodible gel
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
CZ20022046A3 (cs) * 1999-12-23 2002-11-13 Pfizer Products Inc. Hydrogelem hnaná dávková forma účinné sloľky
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
EP1275373A4 (en) * 2000-04-17 2007-04-04 Astellas Pharma Inc DRUG DISPERSION SYSTEM FOR THE AVOIDANCE OF PHARMACOKINETIC INTERACTIONS BETWEEN ACTIVE SUBSTANCES AND METHODOLOGY THEREOF
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
PL374280A1 (en) * 2001-11-13 2005-10-03 Yamanouchi Pharma Technologies, Inc. Soluble drug extended release system
DE60320940D1 (de) * 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
JP4632288B2 (ja) * 2002-02-27 2011-02-16 塩野義製薬株式会社 難水溶性薬物の吸収性を改善した固形状製剤
NZ519363A (en) * 2002-06-05 2004-02-27 Agres Ltd A novel drug dosing regimen
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
PE20040134A1 (es) 2002-07-25 2004-03-06 Pharmacia Corp Forma de dosificacion de una vez al dia de pramipexol
EP1537880A4 (en) 2002-09-11 2009-07-01 Takeda Pharmaceutical PREPARATION FOR PROLONGED RELEASE
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP4459543B2 (ja) * 2003-03-17 2010-04-28 株式会社メドジェル 徐放性ハイドロゲル製剤
JP2007501218A (ja) 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8197846B2 (en) 2003-11-10 2012-06-12 Astellas Pharma Inc. Sustained release pharmaceutical composition
US8128958B2 (en) 2003-11-10 2012-03-06 Astellas Pharma Inc. Sustained release pharmaceutical composition
US20050171248A1 (en) * 2004-02-02 2005-08-04 Yanmei Li Hydrogel for use in downhole seal applications
US20070196396A1 (en) * 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
PT1765292T (pt) 2004-06-12 2017-12-29 Collegium Pharmaceutical Inc Formulações de fármacos dissuasoras de abuso
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
WO2006015277A1 (en) * 2004-07-30 2006-02-09 Baker Hughes Incorporated Downhole inflow control device with shut-off feature
CN101849920A (zh) 2004-08-13 2010-10-06 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
RS51527B2 (sr) 2004-08-13 2018-02-28 Boehringer Ingelheim Int Tabletna formulacija sa produženim otpuštanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so, postupak za proizvodnju iste i njena primena
US20060074182A1 (en) 2004-09-30 2006-04-06 Depuy Products, Inc. Hydrogel composition and methods for making the same
WO2006038596A1 (ja) * 2004-10-05 2006-04-13 Astellas Pharma Inc. 涙液及び唾液乾燥症治療用医薬組成物
US20060128719A1 (en) * 2004-12-13 2006-06-15 Boehringer Ingelheim Pharmaceuticals, Inc. Use of alpha-adrenergic blockers for the treatment of dysmenorrhea
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20060239956A1 (en) * 2005-04-26 2006-10-26 Lulu Henson Preparation and use of hydrogels
US20090117190A1 (en) * 2005-08-23 2009-05-07 Nissan Chemical Industries, Ltd. Sustained-release preparation
EP1946780B1 (en) 2005-11-11 2012-01-11 Asahi Kasei Chemicals Corporation Controlled release solid preparation
GB0607534D0 (en) * 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
EP2026766A1 (en) 2006-05-17 2009-02-25 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
JP5245175B2 (ja) * 2006-11-13 2013-07-24 杏林製薬株式会社 持続放出型錠剤の製造方法
WO2008081829A1 (ja) 2006-12-27 2008-07-10 Astellas Pharma Inc. 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
KR100885029B1 (ko) * 2007-02-07 2009-02-23 지엘팜텍 주식회사 경구투여용 서방성 삼중정제
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US7942206B2 (en) 2007-10-12 2011-05-17 Baker Hughes Incorporated In-flow control device utilizing a water sensitive media
US8096351B2 (en) * 2007-10-19 2012-01-17 Baker Hughes Incorporated Water sensing adaptable in-flow control device and method of use
EP2047847A1 (en) 2007-10-12 2009-04-15 KRKA, tovarna zdravil, d.d., Novo mesto Solid pharmaceutical composition comprising tamsulosin
US8312931B2 (en) * 2007-10-12 2012-11-20 Baker Hughes Incorporated Flow restriction device
US7775271B2 (en) 2007-10-19 2010-08-17 Baker Hughes Incorporated Device and system for well completion and control and method for completing and controlling a well
US7913765B2 (en) * 2007-10-19 2011-03-29 Baker Hughes Incorporated Water absorbing or dissolving materials used as an in-flow control device and method of use
US7891430B2 (en) 2007-10-19 2011-02-22 Baker Hughes Incorporated Water control device using electromagnetics
US8069921B2 (en) * 2007-10-19 2011-12-06 Baker Hughes Incorporated Adjustable flow control devices for use in hydrocarbon production
US8544548B2 (en) * 2007-10-19 2013-10-01 Baker Hughes Incorporated Water dissolvable materials for activating inflow control devices that control flow of subsurface fluids
US7789139B2 (en) 2007-10-19 2010-09-07 Baker Hughes Incorporated Device and system for well completion and control and method for completing and controlling a well
US7784543B2 (en) * 2007-10-19 2010-08-31 Baker Hughes Incorporated Device and system for well completion and control and method for completing and controlling a well
US20090101354A1 (en) * 2007-10-19 2009-04-23 Baker Hughes Incorporated Water Sensing Devices and Methods Utilizing Same to Control Flow of Subsurface Fluids
US7918272B2 (en) * 2007-10-19 2011-04-05 Baker Hughes Incorporated Permeable medium flow control devices for use in hydrocarbon production
US7775277B2 (en) * 2007-10-19 2010-08-17 Baker Hughes Incorporated Device and system for well completion and control and method for completing and controlling a well
US7793714B2 (en) 2007-10-19 2010-09-14 Baker Hughes Incorporated Device and system for well completion and control and method for completing and controlling a well
US7913755B2 (en) 2007-10-19 2011-03-29 Baker Hughes Incorporated Device and system for well completion and control and method for completing and controlling a well
US20090101344A1 (en) * 2007-10-22 2009-04-23 Baker Hughes Incorporated Water Dissolvable Released Material Used as Inflow Control Device
US7918275B2 (en) * 2007-11-27 2011-04-05 Baker Hughes Incorporated Water sensitive adaptive inflow control using couette flow to actuate a valve
MX2010008138A (es) 2008-01-25 2010-08-10 Gruenenthal Gmbh Forma de dosis farmaceutica.
US7597150B2 (en) 2008-02-01 2009-10-06 Baker Hughes Incorporated Water sensitive adaptive inflow control using cavitations to actuate a valve
US8839849B2 (en) * 2008-03-18 2014-09-23 Baker Hughes Incorporated Water sensitive variable counterweight device driven by osmosis
US7992637B2 (en) * 2008-04-02 2011-08-09 Baker Hughes Incorporated Reverse flow in-flow control device
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
US8931570B2 (en) * 2008-05-08 2015-01-13 Baker Hughes Incorporated Reactive in-flow control device for subterranean wellbores
JP5674641B2 (ja) 2008-05-09 2015-02-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 噴霧凝固工程の適用下での中間粉末製剤および最終固体剤形の製造方法
US8113292B2 (en) 2008-05-13 2012-02-14 Baker Hughes Incorporated Strokable liner hanger and method
US7789152B2 (en) 2008-05-13 2010-09-07 Baker Hughes Incorporated Plug protection system and method
US8555958B2 (en) 2008-05-13 2013-10-15 Baker Hughes Incorporated Pipeless steam assisted gravity drainage system and method
US7762341B2 (en) * 2008-05-13 2010-07-27 Baker Hughes Incorporated Flow control device utilizing a reactive media
US8171999B2 (en) * 2008-05-13 2012-05-08 Baker Huges Incorporated Downhole flow control device and method
EP2161019A1 (en) 2008-09-05 2010-03-10 KRKA, D.D., Novo Mesto Prolonged release multiparticulate pharmaceutical composition comprising paliperidone
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US8465770B2 (en) 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
DK2394648T3 (en) 2009-02-04 2016-09-26 Astellas Pharma Inc A pharmaceutical composition for oral administration
EP2255793A1 (en) 2009-05-28 2010-12-01 Krka Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition comprising tamsulosin
US8132624B2 (en) * 2009-06-02 2012-03-13 Baker Hughes Incorporated Permeability flow balancing within integral screen joints and method
US8056627B2 (en) * 2009-06-02 2011-11-15 Baker Hughes Incorporated Permeability flow balancing within integral screen joints and method
US20100300675A1 (en) * 2009-06-02 2010-12-02 Baker Hughes Incorporated Permeability flow balancing within integral screen joints
US20100300674A1 (en) * 2009-06-02 2010-12-02 Baker Hughes Incorporated Permeability flow balancing within integral screen joints
US8151881B2 (en) * 2009-06-02 2012-04-10 Baker Hughes Incorporated Permeability flow balancing within integral screen joints
RU2567723C2 (ru) 2009-07-22 2015-11-10 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
WO2011057131A1 (en) 2009-11-09 2011-05-12 Spotlight Technology Partners Llc Polysaccharide based hydrogels
AU2010314994B2 (en) 2009-11-09 2016-10-06 Spotlight Technology Partners Llc Fragmented hydrogels
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
AU2011219452B2 (en) * 2010-02-24 2014-05-29 Zoetis Llc Veterinary compositions
PT2554168T (pt) 2010-03-29 2018-02-28 Astellas Pharma Inc Composição farmacêutica de libertação controlada
JP5849946B2 (ja) * 2010-03-29 2016-02-03 アステラス製薬株式会社 放出制御医薬組成物
BR112013005234A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo um polímero aniônico.
BR112013005194A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo sal inorgânico
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
EA032906B1 (ru) 2010-12-22 2019-08-30 Пэдью Фарма Л.П. Твердая лекарственная форма с контролируемым высвобождением и способы ее получения и применения
KR101458334B1 (ko) 2010-12-23 2014-11-04 퍼듀 퍼머 엘피 탬퍼 저항성 고체 경구 투여 형태
KR102027912B1 (ko) 2011-02-15 2019-10-02 지엘팜텍주식회사 경구투여용 탐술로신 또는 이의 약제학적으로 허용되는 염을 포함하는 서방성 삼중정제
RU2451680C1 (ru) 2011-02-21 2012-05-27 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
JP6177233B2 (ja) 2011-06-07 2017-08-09 ジェレシス エルエルシー ヒドロゲルを生成するための方法
CN103857386A (zh) 2011-07-29 2014-06-11 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
JP2014524925A (ja) 2011-07-29 2014-09-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
SG10201700121YA (en) 2011-10-21 2017-03-30 Takeda Pharmaceuticals Co Sustained-release preparation
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
JP6123795B2 (ja) * 2012-03-30 2017-05-10 アステラス製薬株式会社 放出制御医薬組成物
LT2838512T (lt) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
RU2653678C2 (ru) * 2012-12-21 2018-05-11 Нестек С.А. Устройство для приготовления молочной пены
US8999393B1 (en) 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
JP6208261B2 (ja) 2013-02-05 2017-10-04 パーデュー、ファーマ、リミテッド、パートナーシップＰｕｒｄｕｅ Ｐｈａｒｍａ Ｌ．Ｐ． タンパリング抵抗性医薬製剤
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
EP3003283A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
BR112015026549A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem à prova de violação contendo uma ou mais partículas
EP3878445A3 (en) 2013-06-05 2021-10-27 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
AU2015261060A1 (en) 2014-05-12 2016-11-03 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising Tapentadol
AU2015266117A1 (en) 2014-05-26 2016-11-24 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
CA2950482C (en) 2014-06-20 2022-12-06 Gelesis, Llc Methods for treating overweight or obesity
DK3215127T3 (da) 2014-11-07 2021-02-01 Sublimity Therapeutics Ltd Sammensætninger omfattende cyclosporin
US10179824B2 (en) 2015-01-29 2019-01-15 Gelesis Llc Method for producing hydrogels coupling high elastic modulus and absorbance
WO2016123482A2 (en) 2015-01-30 2016-08-04 Mylan, Inc. Sustained-release oral dosage forms for low aqueous solubility compounds
EA035434B1 (ru) 2015-04-24 2020-06-15 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
TWI722988B (zh) * 2015-06-05 2021-04-01 瑩碩生技醫藥股份有限公司 緩釋性醫藥組合物及其製備方法
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
CN105770866A (zh) * 2016-04-08 2016-07-20 王夕花 一种缓释型降糖药物组合物及其制备方法
WO2017186598A1 (en) 2016-04-25 2017-11-02 Synthon B.V. Modified release tablet composition comprising mirabegron
CA3022090A1 (en) 2016-04-25 2017-11-02 Gelesis, Llc. Method for treating constipation
WO2017186593A1 (en) 2016-04-25 2017-11-02 Synthon B.V. Tablets comprising mirabegron and solifenacin
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
EP3292864A1 (en) 2017-10-12 2018-03-14 Synthon B.V. Modified release tablet composition comprising mirabegron
CA3078568A1 (en) 2017-10-12 2019-04-18 Synthon B.V. Modified release tablet composition comprising mirabegron
US10478399B2 (en) 2017-10-12 2019-11-19 Synthon B.V. Modified release tablet composition comprising mirabegron
ES2963886T3 (es) 2017-10-17 2024-04-03 Synthon Bv Comprimidos que contienen tamsulosina y solifenacina
AR121207A1 (es) * 2020-01-31 2022-04-27 Nippon Shinyaku Co Ltd Composición de liberación controlada
CN111728949B (zh) * 2020-07-17 2022-10-04 广州帝奇医药技术有限公司 一种难溶性药物口服缓释组合物及其制备方法
PT4255398T (pt) 2020-12-01 2024-10-18 Adamed Pharma S A Preparação administrada oralmente contendo solifenacina e tansulosina
MD4037666T2 (ro) 2020-12-08 2024-09-30 Ruminant Biotech Corp Ltd Îmbunătățiri ale dispozitivelor și metodelor de furnizare a substanțelor la animale
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
BR6570825D0 (pt) * 1964-07-04 1973-08-16 Shiryo Kogyo Co Inc Nippon Processo para produzir granulos cristalizados a partir de solucoes de acucares e outros cristaloides
US3458622A (en) * 1967-04-07 1969-07-29 Squibb & Sons Inc Controlled release tablet
US3619292A (en) * 1968-07-15 1971-11-09 Penick & Ford Ltd Tablets and method of forming
JPS51135900A (en) * 1975-05-19 1976-11-25 Kao Corp Method for prod uction of the stable sodium percarbonate
US4126672A (en) * 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4111201A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
JPS5649314A (en) * 1979-07-05 1981-05-02 Yamanouchi Pharmaceut Co Ltd Lasting pharmaceutical composition having prolonged action and its preparation
DE3280021D1 (en) 1981-06-12 1989-12-21 Nat Res Dev Hydrogels
JPS58189121A (ja) * 1982-04-30 1983-11-04 Ajinomoto Co Inc インシユリン投与賦活剤
US4571333A (en) * 1983-06-14 1986-02-18 Syntex (U.S.A.) Inc. Controlled release naproxen and naproxen sodium tablets
US5002776A (en) * 1983-12-22 1991-03-26 Elan Corporation, Plc Controlled absorption diltiazem formulations
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
SE8601624D0 (sv) 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US4940580A (en) 1986-11-03 1990-07-10 Schering Corporation Sustained release labetalol tablets
DE3776269D1 (de) 1986-11-03 1992-03-05 Schering Corp Labetalol tablette mit verzoegerter wirkstoffabgabe.
JPS63151353A (ja) * 1986-12-15 1988-06-23 Oogawara Kakoki Kk ワツクスコ−テイングマイクロカプセルの製造方法
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4904474A (en) * 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
JPH0283316A (ja) 1988-09-20 1990-03-23 Shin Etsu Chem Co Ltd 徐放性錠剤
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
US5128132A (en) * 1988-11-22 1992-07-07 Parnell Pharmaceuticals, Inc. Eriodictyon compositions and methods for treating internal mucous membranes
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
JPH02282322A (ja) 1989-01-31 1990-11-19 Ipa Internatl Pharma Agentur Gmbh 有効物質の浸食制御による放出システムおよびその製造方法
HU203041B (en) 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
PT93637A (pt) * 1989-04-20 1990-11-20 Procter & Gamble Metodo para o tratamento de desordens funcionais intestinais/colonicas, especialmente o sindrome de irritacao intestinal
JPH0334927A (ja) * 1989-06-29 1991-02-14 Teikoku Seiyaku Kk 潰瘍性大腸炎およびクローン病治療用経口投与組成物
US5000962A (en) * 1989-08-25 1991-03-19 Schering Corporation Long acting diltiazem formulation
US5178866A (en) * 1990-03-23 1993-01-12 Alza Corporation Dosage form for delivering drug to the intestine
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
SE9003904D0 (sv) 1990-12-07 1990-12-07 Astra Ab Method for the manufacture of a pharmaceutical dosage form
US5273758A (en) * 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
JP2916290B2 (ja) * 1991-03-22 1999-07-05 帝國製薬株式会社 生理活性ポリペプチド含有大腸崩壊経口製剤
JPH05255125A (ja) * 1992-02-29 1993-10-05 Upjohn Co:The 徐放性製剤およびその製法
JPH05262767A (ja) 1992-03-19 1993-10-12 Takeda Chem Ind Ltd 持続性製剤
JPH08502082A (ja) 1992-07-02 1996-03-05 コラーゲン コーポレイション 生体適合性ポリマー結合体
DE4226753A1 (de) 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
RO112991B1 (ro) * 1992-09-18 1998-03-30 Yamanouchi Pharma Co Ltd Preparat tip hidrogel, cu eliberare sustinuta
EP0621032B1 (en) * 1993-04-23 2000-08-09 Novartis AG Controlled release drug delivery device
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物

Also Published As

Publication number Publication date
CN1091004A (zh) 1994-08-24
NO951036D0 (no) 1995-03-17
RU2121830C1 (ru) 1998-11-20
EP0661045A4 (en) 1997-02-26
SK281042B6 (sk) 2000-11-07
BG61861B1 (bg) 1998-08-31
JP3140465B2 (ja) 2001-03-05
RO112991B1 (ro) 1998-03-30
FI115697B (fi) 2005-06-30
DE69332081T2 (de) 2003-02-06
ATE219933T1 (de) 2002-07-15
FI951226A (fi) 1995-03-16
NO951036L (no) 1995-03-17
AU4983893A (en) 1994-04-12
AU682827B2 (en) 1997-10-23
CA2144077C (en) 2005-05-24
NZ255579A (en) 1996-03-26
WO1994006414A1 (en) 1994-03-31
FI951226A0 (fi) 1995-03-16
US6436441B1 (en) 2002-08-20
US20030203024A1 (en) 2003-10-30
EP0661045A1 (en) 1995-07-05
BG99503A (bg) 1996-01-31
HU9500808D0 (en) 1995-05-29
EP0661045B1 (en) 2002-07-03
CZ67995A3 (en) 1995-09-13
US6699503B1 (en) 2004-03-02
CA2144077A1 (en) 1994-03-31
KR100355130B1 (ko) 2003-01-30
PL308137A1 (en) 1995-07-24
SK33895A3 (en) 1995-11-08
PT661045E (pt) 2002-11-29
HU226456B1 (en) 2008-12-29
PL175026B1 (pl) 1998-10-30
CZ291495B6 (cs) 2003-03-12
NO312811B1 (no) 2002-07-08
DK0661045T3 (da) 2002-10-28
ES2179829T3 (es) 2003-02-01
HUT72324A (en) 1996-04-29
CN1048397C (zh) 2000-01-19
DE69332081D1 (de) 2002-08-08

Similar Documents

Publication Publication Date Title
KR950703331A (ko) 하이드로겔 서방성 제제(Sustained-release hydrogel preparation)
RU95109153A (ru) Гидрогелевый препарат с длительным высвобождением лекарства
RU2085191C1 (ru) Жидкая антибактериальная композиция
ES2437791T3 (es) Cápsula dura
Mayol et al. A novel poloxamers/hyaluronic acid in situ forming hydrogel for drug delivery: Rheological, mucoadhesive and in vitro release properties
US5653992A (en) Liquid absorbable copolymers for parenteral applications
US5919481A (en) Fill material for soft gelatin pharmaceutical dosage form
CA2422356C (en) Suppository of retaining in lower region of rectum
JPH08253411A (ja) 軟質ゼラチン医薬製剤
CA2143500C (en) Expandable pharmaceutical forms
EP0815855B1 (en) Multiphase soft gelatin dosage form
CZ210496A3 (en) Method improving solution process of difficult-to dissolve pharmaceutically active compounds
US6488954B1 (en) Liquid suppository composition of diclofenac sodium
JP3100416B2 (ja) ムース状潤滑剤
Firsov et al. Biodegradable implants containing gentamicin: drug release and pharmacokinetics
JP2021536485A (ja) 注射可能な徐放性の抗生物質製剤
US5908636A (en) Fill material for soft gelatin pharmaceutical dosage form containing an antiflatulent
Ibrahim et al. Formulation, release characteristics and evaluation of ibuprofen suppositories
JP4552322B2 (ja) 坐剤
KR100214714B1 (ko) 신규한 국소마취제 함유 겔제제
JPH01186823A (ja) 薬物透過性物質の製造方法
EP1541144B1 (en) Indometacin external preparation
JP4929533B2 (ja) 多価アルコール含有ゲル状基剤
JPS59122420A (ja) 局所軟膏剤
US20160339151A1 (en) Hydrogel having a decomposition rate capable of being regulated in situ and method for manufacturing same

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120907

Year of fee payment: 11

EXPY Expiration of term